Trial Profile
A Phase II, Multi-center, Open-label Study Evaluating GRN1005 Alone or in Combination With Trastuzumab in Breast Cancer Patients With Brain Metastases
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Paclitaxel trevatide (Primary) ; Trastuzumab
- Indications Advanced breast cancer; Brain metastases; HER2 negative breast cancer; HER2 positive breast cancer; Meningeal carcinomatosis
- Focus Therapeutic Use
- Acronyms GRABM-B
- Sponsors AngioChem
- 22 Jan 2020 Results assessing efficacy of ANG1005 in patients with breast cancer with leptomeningeal carcinomatosis and recurrent brain metastases, published in the Clinical Cancer Research.
- 03 Jun 2016 Status changed from active, no longer recruiting to completed.
- 09 Nov 2015 Results of a biomarker sub-study (n=10) presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2015.